ArticlePsychopharmacology2019
A translational EEG-based approach to assess modulation of long-lasting NMDAR-dependent synaptic plasticity.
Article in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06957808 (Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- New advances in small molecule drugs targeting NMDA receptors.Acta pharmacologica Sinica · 2026Review
- Exploring NMDAR pathways in ischemic stroke: implications for neurotoxic and neuroprotective mechanisms and therapeutic strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- PSD-95 Protein: A Promising Therapeutic Target in Chronic Pain.Molecular neurobiology · 2025Review
- What do ultrasound vocalizations really mean in rats with different origins of pain?Pain reports · 2025Article
- Neuroplastic effects of transcranial alternating current stimulation (tACS): from mechanisms to clinical trials.Frontiers in human neuroscience · 2025Review
- Targeting metaplasticity mechanisms to promote sustained antidepressant actions.Molecular psychiatry · 2024Review
- A prefrontal cortex alpha/delta switch controls the transition from positive to negative affective states.Discover mental health · 2023Article
- An IGFBP2-derived peptide promotes neuroplasticity and rescues deficits in a mouse model of Phelan-McDermid syndrome.Molecular psychiatry · 2023Article
- Neuromodulatory effects and reproducibility of the most widely used repetitive transcranial magnetic stimulation protocols.PloS one · 2023Article
- Opposite effects of rapid auditory stimulation on tetanized and non-tetanized tone of adjacent frequency: Mismatch negativity study.PloS one · 2023Article
- Unmasking hidden risks: The surprising link between PDE5 inhibitors and seizure susceptibility.PloS one · 2023Article
- Anesthesia and analgesia for experimental craniotomy in mice and rats: a systematic scoping review comparing the years 2009 and 2019.Frontiers in neuroscience · 2023Article
- Article
- Generalization of sustained neurophysiological effects of short-term auditory 13-Hz stimulation to neighbouring frequency representation in humans.The European journal of neuroscience · 2022Article
- Life-long brain compensatory responses to galactic cosmic radiation exposure.Scientific reports · 2021Article
- Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in SchizophreniaJournal of psychiatry and brain science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundNYX-2925 is a novel N-methyl-D-aspartate receptor (NMDAR) modulator that has been shown to facilitate both NMDAR-dependent long-term potentiation (LTP) in vitro and learning and memory in vivo.
objectiveThe present studies examine the effects of NYX-2925 on NMDAR-dependent auditory LTP (aLTP) in vivo.
methodsNMDAR-dependent aLTP and NMDAR-dependent auditory mismatch negativity (MMN) was measured, as well as changes in resting-state qEEG power.
resultsNYX-2925 (1, 10 mg/kg PO) increased aLTP 1 h after auditory tetanus measured by the post- minus pre-tetanus difference waveform 140-180 ms post tone onset. NYX-2925 (0.1, 1 mg/kg PO) facilitated MMN measured by the difference waveform (i.e., deviant minus standard tones). NYX-2925 (0.1, 1, 10 mg/kg PO) also enhanced resting-state alpha qEEG power. Conversely, the NMDAR glutamate site antagonist CPP (10 mg/kg IP) reduces alpha power and MMN and produces an opposite effect as NYX-2925 on aLTP.
conclusionsTogether, these data suggest that the activation of the NMDAR by NYX-2925 enhances synaptic plasticity in vivo, which may both reduce symptoms of neurological disorders and serve as a biomarker for drug effects. This is the first demonstration of a long-lasting (1-h post-tetanus) effect of NMDAR modulation on synaptic plasticity processes in vivo using a noninvasive technique in freely behaving animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.